5 Essential Elements For ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC)
These side effects have been notably milder as compared to an inhibitor of the two bromodomains. An in depth molecular Assessment also uncovered that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor88 These preclinical studies offer paradigms for foreseeable future clinical trials in AM